BrightGene has continuously received a Wind ESG A rating, with a comprehensive score of 7.53同壁财经·May 30 at 10:12 AM688166+3.49%
02:08 ETGIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arenaprnewswire·May 12 at 01:10 AM688166+3.49%
12:10 ET19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilitiesprnewswire·May 6 at 11:12 AM688166+3.49%
08:20 ETBGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpointsprnewswire·May 5 at 07:22 AM688166+3.49%
BGM0504 Injection Achieves Phase III Clinical Trial Goals for Weight LossCoinLive·May 5 at 04:13 AM688166+3.49%
April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally CollectivelyWallstreetcn·Apr 14 at 10:30 PM688166+3.49%000919+1.62%
02:32 ETBrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United Statesprnewswire·Mar 25 at 01:33 AM688166+3.49%
BrightGene: Plans to repurchase shares worth 10 million to 20 million yuan, has repurchased nearly 3 million yuanZhitong·Nov 3, 2025 at 01:46 AM688166+3.49%
BrightGene: Net profit in the third quarter was 33.1468 million yuan, a year-on-year decrease of 53.34%Zhitong·Oct 30, 2025 at 06:54 AM688166+3.49%
BrightGene: Subsidiary BrightGene Pharmaceutical's product Dydrogesterone Tablets is expected to win the bid for national centralized drug procurementZhitong·Oct 28, 2025 at 05:56 AM688166+3.49%
BrightGene terminates the review of stock issuance to specific objectsZhitong·Oct 20, 2025 at 03:35 AM688166+3.49%
BrightGene: Termination of the issuance of A-shares to specific targets for the year 2024Zhitong·Oct 15, 2025 at 05:15 AM688166+3.49%
BrightGene: BGM1812 injection has received FDA approval for clinical trials in the United StatesZhitong·Sep 29, 2025 at 02:44 AM688166+3.49%
